Asimov is a Boston-based bioengineering company with the mission to enable biotechnologies with outsized societal benefits. The company's synthetic biology platform integrates libraries of proprietary genetic components, computer-aided design software and large generative artificial intelligence (AI) models. These biology and software capabilities are licensed as a bundle to biotech companies to augment and accelerate therapeutic development. Founded by bioengineers from MIT and Boston University, Asimov has raised over $200 million from institutional investors including Andreessen Horowitz, CPP Investments, Horizons Ventures, and Fidelity Management & Research Company.